Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients

Blood

Volumn 117, Issue 22, 2011, Pages 5857-5859

  Carobbio, Alessandra ^a   Thiele, Juergen ^b   Passamonti, Francesco ^c   Rumi, Elisa ^c   Ruggeri, Marco ^d   Rodeghiero, Francesco ^d   Randi, Maria Luigia ^e   Bertozzi, Irene ^e   Vannucchi, Alessandro M ^f   Antonioli, Elisabetta ^f   Gisslinger, Heinz ^g   Buxhofer Ausch, Veronika ^g   Finazzi, Guido ^a   Gangat, Naseema ^h   Tefferi, Ayalew ^h   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF PAVIA   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

EID: 79957975519     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-339002     Document Type: Article

References (12)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
3. Barbui T, Thiele J, Passamonti F, et al. Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1104 patients [abstract]. ASH Annual Meeting Abstracts. 2010;116:457.
4. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45. (Pubitemid 41007805)
5. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135-3137.
6. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.
7. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood. 2007;109(9):4105. (Pubitemid 46641767)
8. Alvarado CM, Diaz JA, Hawley AE, Wrobleski SK, Sigler RE, Myers DD Jr. Male mice have increased thrombotic potential: sex differences in a mouse model of venous thrombosis. Thromb Res. 2011;127(5):478-486.
9. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315-318.
10. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
11. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205-1210; quiz 1387.
12. Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986;68(6):1213-1217. (Pubitemid 17228794)